# US 2019/0376048 A1 · Three-dimensional in vitro lung model, process for preparing said model, and its use for determining and /or predicting the sensitizing effects of inhalable products

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376048 A1
- Document ID: US20190376048A1
- Status: Published application
- Kind: A1
- Application number: 16/472,335
- Filed: 2017-12-26
- Published: 2019-12-12
- Earliest claimed: 2016-12-27
- Assignees: Luxembourg Institute of Science and Technology
- Applicants: Luxembourg Institute of Science and Technology
- Inventors: Aline CHARY; Arno GUTLEB; Tommaso SERCHI; Brunhilde BLOMEKE
- Web page: https://patentgrep.com/patent/US20190376048A1

## CPC

- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 5/0688: {Cells from the lungs or the respiratory tract}
- C12N 2502/1114: T cells
- C12N 2502/1121: Dendritic cells
- C12N 2502/1157: Monocytes, macrophages
- C12N 2502/27: Lung cells, respiratory tract cells
- C12N 2502/28: Vascular endothelial cells
- C12N 2503/04: Screening or testing on artificial tissues
- G01N 33/5088: {of vertebrates}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a three-dimensional in vitro alveolar lung model comprising essentially the four cells types as follows: alveolar type II epithelial cells able to secrete (lung laying) surfactant, endothelial cells which forms the inner lining of capillaries providing a permeable barrier, dendritic-like cells, such as non-differentiated THP-1, linking innate and adaptive immunity and macrophage-like cells, able to participate to defense mechanisms by ingesting foreign materials by phagocytosis. The invention also relates to a process for preparing said model, and its use for assessing the irritation potential or toxicity of inhalable products such as particles or molecules on the alveolar barrier of lungs, and also for determining and/or predicting the sensitizing effects of inhalable products such as particles or molecules on the alveolar barrier of lungs.

## Claims

### Claim 1

A three-dimensional in vitro alveolar lung model comprising:
mainly the four cells types as follows:
a) alveolar type II epithelial cells able to secrete surfactant,
b) endothelial cells which form the inner lining of capillaries providing a permeable barrier
c) dendritic-like cells,
d) macrophage-like cells, able to participate to defense mechanisms by ingesting foreign materials by phagocytosis, wherein:
said three-dimensional in vitro lung model is in the form of a culture well equipped with a porous membrane separating the well into an apical compartment exposed to an air-liquid interface, and a basolateral compartment submerged in a culture medium, said epithelial cells and said macrophages being present in the apical compartment, and said endothelial cells and said dendritic-like cells being present at the basolateral compartment and immerge in the culture medium,
said porous membrane has pores comprised between 2 and 10 μm, allowing possible migration of the dendritic-like cells from the basolateral compartment to the apical compartment.

### Claim 2 (depends on 1)

The model according to claim 1 wherein macrophage-like cells are THP-1 cells, differentiated with PMA (Phorbol-12-myristate-13-acetate) or with 1,25-dihydroxyvitamin D3, preferably differentiated with PMA.

### Claim 3 (depends on 1)

The model according to claim 1, wherein all cells are immortalized human cell lines.

### Claim 4 (depends on 1)

The model according to claim 1, wherein said alveolar type II epithelial cells are A549 cells.

### Claim 5 (depends on 1)

The model according to claim 1, wherein said endothelial cells are EA.hy926 cells.

### Claim 6 (depends on 1)

The model according to claim 1, wherein said dendritic-like cells are non-differentiated THP-1 cells.

### Claim 7 (depends on 1)

The model according to claim 1, wherein the porous membrane has pores comprised between 3 and 8 μm.

### Claim 8 (depends on 1)

A process for preparing the three-dimensional in vitro alveolar lung model as defined in claim 1, comprising co-culture of cells a)-d) in an insert having a porous membrane, in the following step sequence:
i) seeding the lower face (which will become the basolateral side) of a membrane insert having pores comprised between 2 and 10 μm with 0.24 105 to 0.6 105 endothelial cells/cm2,
ii) at least four hours later, seeding the other side (apical side) of the membrane insert with the alveolar type II epithelial cells, preferably 0.12 105 to 1.2 105, preferably 0.5 105 to 1.0 105/cm2 cells,
iii) about 4 days later, adding a cell suspension containing between 0.1 and one million dendritic-like cells/mL to the basolateral side of the membrane insert, and then
iv) adding macrophage-like cells on top of the alveolar type II epithelial cells seed, preferably 0.12 105 to 1.2 105 macrophage-like cells/cm2, and finally,
v) introduce the membrane insert in a medium in order that said endothelial cells and said dendritic-like cells are (present at the basolateral compartment) immerged in the co-culture medium, and said epithelial cells and said macrophages-like are present in the apical compartment, at the air-liquid interface.

### Claim 9 (depends on 8)

The process according to claim 8, wherein said macrophage-like cells are THP-1 cells, differentiated with PMA (Phorbol-12-myristate-13-acetate), and/or said alveolar type II epithelial cells are A549 cells, and/or said endothelial cells are EA.hy926 cells, and/or said dendritic-like cells are non-differentiated THP-1 cells.

### Claim 10 (depends on 1)

Use of a three-dimensional in vitro alveolar lung model as defined in claim 1, for assessing the irritation potential or toxicity of inhalable products on the alveolar barrier of lungs.

### Claim 11 (depends on 1)

Use of a three-dimensional in vitro alveolar lung model according to claim 1 for determining and/or predicting the sensitizing effects of inhalable products on the alveolar barrier of lungs.

### Claim 12 (depends on 1)

A process for determining and/or predicting the sensitizing effects, and/or the irritation potential or toxicity, of inhalable products on the alveolar barrier of lungs, comprising:
A) a step of exposing by pulverizing/nebulizing the inhalable product to be tested over the apical compartment of a three-dimensional in vitro alveolar lung model as defined in claim 1, in the form of a culture well equipped with a porous membrane having pores comprised between 2 and 10 μm, said epithelial cells and said macrophages being present at the apical side of the membrane, and said endothelial cells and said dendritic-like cells being present at the basal side of the membrane, said endothelial cells and said dendritic-like cells being immerged in the co-culture medium, said exposing leading to activation of the dendritic-like cells,
B) a step of co-culturing said activated dendritic-like cells with a T lymphoblast cell line.

### Claim 13 (depends on 12)

The process according to claim 12, wherein T-cells present a Helper type 2 (TH2) profile if the product to be tested is a suspected respiratory sensitizer.

### Claim 14 (depends on 12)

The process according to claim 12, wherein markers for the respiratory sensitization potential are measured by FACS (CD40, CD54, CD86, TSLPr, IL-1ra, OX40L) and/or by ELISA (TSLP, IL-33, IL-25, RANTES, MCP-1, MIP-3a, IL-6, IL-7, IL-10 and GM-CSF).

### Claim 15 (depends on 12)

The process according to claim 12, wherein further biological endpoints comprising release of interleukins, genotoxicity, biomarkers of sensitization, proteomics, transcriptomics and metabolic activation are measured.
